Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.
We love Rheumatology!
All News
Article
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Article
Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h
Dr. John Cush
Tweet
Join us this Tuesday for Tuesday Night Rheumatology focusing on Spondyloarthritis with sessions from Dr. Nigil Haroon, Dr. Artie Kavanaugh, and Dr. Robert Wang.
https://t.co/Jr6H0Yg6xs https://t.co/UXx37liLSZ
Dr. John Cush
Tweet
RNL 2021 - Spondyloarthritis Q & A Panel Discussion
https://t.co/3oFZNV0XI6
Dr. John Cush
Tweet
New podcast available— BandAids for Rheumatologists. Listen on SoundCloud and wherever podcasts are available.
https://t.co/AGROPnfAAi
Dr. John Cush
Tweet
RNL 2021: EULAR 2019 and ACR 2020 RA Treatment Guidelines - Dr. Alan Matsumoto
Dr. Alan Matsumoto presents EULAR 2019 and ACR 2020 RA Treatment Guidelines at the 2021 RheumNow Live meeting.
https://t.co/1swZIWGWKc
Dr. John Cush
Tweet
Cerecor has launched a c Phase 1b clinical trial (NCT04752371) of the human mAb CERC-007, targeting IL-18, in 12 patients with active adult onset Still’s disease (AOSD). They estimate AOSD affects 3,500 - 7,000 in the US 3,400 - 6,900 pts in Europe https://t.co/DlW1QbXOG0
Dr. John Cush
Tweet
CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose (Pfizer, Moderna) and 94% for TWO doses (same as RCTs). The efficacy of only 1 dose (of a 2 dose COVID vax) is likely to be 70- 82%. https://t.co/uQhUmjSsRd
Dr. John Cush
Tweet
Dr. Mike Putman - TULIP Trials - Anifrolumab in SLE
https://t.co/cqZiulDMFm
#LupusAwarenessMonth https://t.co/kNKLUSOKWp
Dr. John Cush
Tweet
Clinical practice data study of 855 Psoriatic arthritis patients. With no differences in treatment, women has worse disease activity score (vs M) (PASDAS 3.5 vs 2.7; p < 0.001). Higher BMI assoc w/ no reaching Low Dz activity in Women, not men. https://t.co/CVAEHhjqCH
Dr. John Cush
Tweet
Worth sharing again-- ACR Updates COVID-19 Vaccine Guidance- April 2021
The ACR COVID-19 Vaccine Clinical Guidance was originally published on 2/8/21 & updated on 3/4/21. On 4/28/21, new recommendations were added.
https://t.co/BgrFxCgjRw https://t.co/O7ngEBEX6s
Dr. John Cush
Tweet
Johns Hopkins researchers suggest that treating refractory dermatomyositis with a JAK inhibitor may improve calcinosis. Based on 3 case reports, who had either NXP2 or TIF-1γ refractory DM, all improved their skin, muscle dz and calcinosis. https://t.co/P5k5y0HS6A
Dr. John Cush
Tweet
News Feature: Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease
https://t.co/ps8JeRUtJf https://t.co/Sn6ykG9ZuE
Dr. John Cush
Tweet
Sulfasalazine may be in short supply. FDA shortage lists shortage with drug return in July or 4th quarter of 2021. ASHP site also notes several generic maker shortages but they suggest resolution mid-May or July https://t.co/XYyraO6Z4z https://t.co/tm50S7ov9K https://t.co/QPWIitYkpp
Dr. John Cush
Tweet
News Feature: Insurers Bet Big on Bribing Patients
https://t.co/Tcip2xODF1 https://t.co/Ieh7yZfurk
Dr. John Cush
Tweet
Dr. Janet Pope - Comorbidities in SLE
From ACR 2019
https://t.co/1BjfVOfL4i https://t.co/CRqUKeYUmi
Dr. John Cush
Tweet
5 Reasons to see Rheumatologist
1. Unexplained, worsening joint or muscle pains
2. Repeated, joint pain/swelling, fevers, rashes
3. Establish early Dx to your chronic joint complaints
4. Review abnormal labs, get a treatment plan
5. Attacks of gout https://t.co/gRVtnM4i7J
Dr. John Cush
Tweet
Dr. Kathryn Dao - Lupus Pearls from ACR 2019
https://t.co/JDlfjAO0xe
#LupusAwarenessMonth https://t.co/1ZiZiNvYhv
